呼吸道感染疾病治疗药物市场：依药物、适应症、通路划分 - 全球预测 2023-2030

预计2023年全球呼吸道感染疾病治疗药物市场将大幅成长453.3亿美元，年复合成长率为7.78%，预计到2030年将达到767亿美元。

FPNV定位矩阵

FPNV 定位矩阵对于评估全球呼吸道感染疾病治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球呼吸道感染疾病治疗药物市场规模及预测为何？

2.在预测期内，COVID-19对全球呼吸道感染疾病治疗药物市场的阻碍因素与影响有哪些？

3.在预测期内，全球呼吸道感染疾病治疗药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球呼吸道感染疾病药物市场的竞争策略为何？

5. 全球治疗呼吸道感染疾病药物市场的技术趋势和法律规范是什么？

6.全球呼吸道感染疾病治疗药物市场主要厂商的市占率为何？

7. 哪些型态和策略措施被认为适合进入呼吸道感染疾病药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 气喘和呼吸道感染疾病的报告增加
    • 改变生活方式和老年人口
    • 该领域仿製药和生物相似药的开发力道加大
  • 抑制因素
    • 季节性展示与检验
  • 机会
    • 投资药物开发和商业化
    • 药物输送系统的技术开发
  • 任务
    • 抗菌素抗药性的出现
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章呼吸道感染疾病治疗药品市场（依药品）

• 抗生素
• 止咳药
• 鼻减充血剂
• 非类固醇消炎剂

第7章感染疾病治疗药物市场：依疾病适应症

• 下呼吸道感染疾病
• 上呼吸道感染疾病

第8章呼吸道感染疾病治疗药物市场：按分销管道

• 医院药房
• 网路药房
• 零售药房

第9章北美和南美呼吸道感染疾病治疗药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第10章亚太呼吸道感染疾病治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第11章欧洲、中东和非洲呼吸道感染疾病治疗市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第12章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

• 讨论指南
• 关于许可证和定价

The Global Respiratory Tract Infection Therapeutic Market is forecasted to grow significantly, with a projected USD 45.33 billion in 2023 at a CAGR of 7.78% and expected to reach a staggering USD 76.70 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Respiratory Tract Infection Therapeutic Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Respiratory Tract Infection Therapeutic Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drugs, market is studied across Antibiotics, Cough Suppressants, Nasal Decongestants, and Non-Steroidal Anti-Inflammatory Drugs. The Non-Steroidal Anti-Inflammatory Drugs is projected to witness significant market share during forecast period.

Based on Disease Indication, market is studied across Lower Respiratory Tract Infection and Upper Respiratory Tract Infection. The Upper Respiratory Tract Infection is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Respiratory Tract Infection Therapeutic Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Tract Infection Therapeutic Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Tract Infection Therapeutic Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Tract Infection Therapeutic Market?

4. What is the competitive strategic window for opportunities in the Global Respiratory Tract Infection Therapeutic Market?

5. What are the technology trends and regulatory frameworks in the Global Respiratory Tract Infection Therapeutic Market?

6. What is the market share of the leading vendors in the Global Respiratory Tract Infection Therapeutic Market?

7. What modes and strategic moves are considered suitable for entering the Global Respiratory Tract Infection Therapeutic Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Respiratory Tract Infection Therapeutic Market, by Drugs, 2022 vs 2030
• 4.3. Respiratory Tract Infection Therapeutic Market, by Disease Indication, 2022 vs 2030
• 4.4. Respiratory Tract Infection Therapeutic Market, by Distribution Channel, 2022 vs 2030
• 4.5. Respiratory Tract Infection Therapeutic Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased reports cases of asthma and respiratory tract infection
    • 5.1.1.2. Changing Lifestyle and geriatric population
    • 5.1.1.3. Increase development of generic drugs and biosimilars in the space
  • 5.1.2. Restraints
    • 5.1.2.1. Seasonal indications and inspections
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in drug development and commercialization
    • 5.1.3.2. Technology development in drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Emergence of antimicrobial resistance
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Respiratory Tract Infection Therapeutic Market, by Drugs

• 6.1. Introduction
• 6.2. Antibiotics
• 6.3. Cough Suppressants
• 6.4. Nasal Decongestants
• 6.5. Non-Steroidal Anti-Inflammatory Drugs

7. Respiratory Tract Infection Therapeutic Market, by Disease Indication

• 7.1. Introduction
• 7.2. Lower Respiratory Tract Infection
• 7.3. Upper Respiratory Tract Infection

8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Respiratory Tract Infection Therapeutic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Tract Infection Therapeutic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2022 VS 2030
• FIGURE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2030 (%)
• FIGURE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
• FIGURE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
• FIGURE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 27. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 144. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 145. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET LICENSE & PRICING